You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.
The company hopes the collaboration will allow it to home in on a molecularly defined population of patients likely to benefit from its targeted agent LP-184.
The signature may be useful for guiding treatment strategy based on patients' prognoses, and with further validation, may even be useful for predicting response to specific drugs.
As MacroGenics advances flotetuzumab through AML studies, it is working with researchers to refine the predictive ability of the gene expression signature.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Using RNA sequence data from the Cancer Genome Atlas and the Chinese Glioma Genome Atlas, researchers identified six genes with expression ties to overall survival.
A new analysis of transcriptome and tumor growth data uncovered distinct expression-based tumor clusters and treatment responses in males and females.